Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...

The marketing battle over the newest drugs to lower cholesterol levels is on. Source: Regeneron Pharmaceuticals. Sanofiand Regeneron Pharmaceuticals' Praluent was approved by the Food and Drug ...

Forty years after the first statin drug started lowering levels of artery-choking cholesterol, heart attacks and strokes remain the world’s biggest killers. This year, we’ll see test results on some ...

The PCSK9 inhibitor market has to date not made good on its major sales promise, with the likes of Amgen and Sanofi in a price-cutting war for the heart drugs. Despite large outcome trials showing a ...

Conquering cholesterol is one of the biggest challenges facing cardiovascular disease patients, and a new study conducted by Amgen Inc. (NASDAQ: AMGN) shows that its cholesterol-busting drug Repatha ...

Nov 14 (Reuters) - A potentially powerful new approach to lower cholesterol by blocking a protein called PCSK9 gained ground, as a new drug from Amgen Inc cut levels of "bad" LDL cholesterol by almost ...

Most heart disease drugs are aimed at reducing "bad" low-density lipoprotein (LDL) cholesterol. But AstraZeneca figures that strategy alone still leaves patients with a meaningful risk of suffering ...

Please provide your email address to receive an email when new articles are posted on . Less frequent anti-PCSK9 monoclonal antibody dosing is possible with recaticimab. When dosed every 12 weeks, the ...